• Users Online: 156
  • Print this page
  • Email this page
REVIEW FOR THE SHEIKH HAMDAN BIN RASHID AL MAKTOUM AWARD FOR MEDICAL SCIENCES
Year : 2014  |  Volume : 7  |  Issue : 3  |  Page : 317-331

Discovery of first-in-class therapeutics – venlafaxine (Effexor®), desvenlafaxine (Pristiq®), temsirolimus (Toresil®), ILS-920 and gemtuzumab ozogamicin (Mylotarg®)


Moulder Center for Drug Discovery Research, School of Pharmacy, Temple University, Philadelphia, PA, USA

Correspondence Address:
Magid Abou-Gharbia
Moulder Center for Drug Discovery Research, School of Pharmacy, Temple University, Philadelphia, PA
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.7707/hmj.346

Rights and Permissions

The pharmaceutical industry today is experiencing unprecedented difficulty and faces enormous challenges, which include the industry's declining efficiencies, patent expirations for key drugs, fierce price competition from generic drugs, mergers and acquisitions, high regulatory hurdles, declining innovation and the industry's perceived tarnished image. Pharma has embarked on a range of initiatives to address these challenges, maintain its commitment to innovation and continue its mission to alleviate human suffering through the discovery of new medicines. This review covers the following themes: (1) drug discovery – highlighting process, targets, approach and current pharmaceutical platforms (small molecules, biologics and vaccines); (2) today's realities – highlighting current challenges facing the pharmaceutical industry, especially the innovation gap, and Pharma's commitment to innovation; (3) commitment to innovation and success stories focusing on selected examples of first-in-class therapeutics, such as the serotonin–noradrenaline reuptake inhibitor antidepressants venlafaxine (Effexor®, Pfizer, Surrey, UK) and desvenlafaxine (Pristiq®, Pfizer, Surrey, UK), immunophilin mammalian target of rapamycin modulator temsirolimus (Toresil®, Pfizer, Surrey, UK), the neuroprotectant ILS-920 for stroke therapy and the first conjugate anticancer drug gemtuzumab ozogamicin (Mylotarg®, Pfizer, Surrey, UK). Although many high drug discovery hurdles remain, the future holds great promise. The search continues for major breakthrough therapies that address unmet medical needs, such as disease-halting drugs for the treatment of Alzheimer's disease, drugs to eradicate hepatitis C and acquired immune deficiency syndrome, and drugs to attack resistant cancers, treat strokes and alleviate cardiovascular disease.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed83    
    Printed5    
    Emailed0    
    PDF Downloaded10    
    Comments [Add]    

Recommend this journal